Literature DB >> 23143476

Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines.

Robert Sealy1, Richard J Webby, Jeri C Crumpton, Julia L Hurwitz.   

Abstract

Currently, there are two different types of licensed influenza virus vaccines available in the USA, the live attenuated cold-adapted vaccine and the inactivated vaccine. Children greater than 2 years of age and adults younger than 50 years (apart from those suffering from immunodeficiencies or lung disease) may choose between the two vaccines. Previous studies have shown that both vaccines elicit significant serum antibody responses. However, comprehensive analyses of antibody-forming cells (AFCs) in the upper respiratory tract (URT), the critical site of pathogen entry, have been lacking. We therefore compared influenza virus-specific antibody and AFC activities in systemic and mucosal tissues following immunizations of cotton rats with inactivated or live-attenuated vaccines, including vaccines from the 2009-10 and 2010-11 seasons. Results demonstrated that inactivated and live-attenuated vaccines induced virus-specific AFCs, but patterns of residence and function were highly disparate. The inactivated vaccine elicited AFCs predominantly in the spleen and bone marrow; IgG was the main isotype. In contrast, the live attenuated vaccine elicited acute and long-sustained AFC responses in the diffuse nasal-associated lymphoid tissue (d-NALT) and lung, with IgA being the predominant isotype. The appearance of these d-NALT URT responses was confirmed by a similar study of the 2009-10 live attenuated vaccine in ferrets. Data emphasize that the inactivated and live-attenuated vaccines that are each capable of protecting humans from influenza virus disease do so by very different modes of immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143476      PMCID: PMC3579181          DOI: 10.1093/intimm/dxs107

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  50 in total

1.  Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.

Authors:  S Tamura; H Funato; Y Hirabayashi; Y Suzuki; T Nagamine; C Aizawa; T Kurata
Journal:  Eur J Immunol       Date:  1991-06       Impact factor: 5.532

2.  Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.

Authors:  W M Kast; L Roux; J Curren; H J Blom; A C Voordouw; R H Meloen; D Kolakofsky; C J Melief
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  Isolation and characterization of mouse nasal-associated lymphoid tissue.

Authors:  H Asanuma; A H Thompson; T Iwasaki; Y Sato; Y Inaba; C Aizawa; T Kurata; S Tamura
Journal:  J Immunol Methods       Date:  1997-03-28       Impact factor: 2.303

4.  Mitogen- and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: evidence for directed heavy chain class switching.

Authors:  S Lutzker; P Rothman; R Pollock; R Coffman; F W Alt
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

5.  Passive transfer of local immunity to influenza virus infection by IgA antibody.

Authors:  K B Renegar; P A Small
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

6.  Patterns of isotype expression by B cell clones responding to thymus-dependent and thymus-independent antigens in vitro.

Authors:  J L Hurwitz; V B Tagart; P A Schweitzer; J J Cebra
Journal:  Eur J Immunol       Date:  1982-04       Impact factor: 5.532

7.  Respiratory virus infection of mice provokes a permanent humoral immune response.

Authors:  L Hyland; M Sangster; R Sealy; C Coleclough
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Bone marrow is a major site of long-term antibody production after acute viral infection.

Authors:  M K Slifka; M Matloubian; R Ahmed
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract.

Authors:  M B Mazanec; M E Lamm; D Lyn; A Portner; J G Nedrud
Journal:  Virus Res       Date:  1992-04       Impact factor: 3.303

View more
  17 in total

1.  Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice.

Authors:  S L Surman; B G Jones; R E Sealy; R Rudraraju; J L Hurwitz
Journal:  Vaccine       Date:  2014-03-21       Impact factor: 3.641

Review 2.  The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms.

Authors:  T D Randall; R E Mebius
Journal:  Mucosal Immunol       Date:  2014-02-26       Impact factor: 7.313

3.  Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

Authors:  Wenqian He; Caitlin E Mullarkey; J Andrew Duty; Thomas M Moran; Peter Palese; Matthew S Miller
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

4.  Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging study.

Authors:  Crystal W Burke; Mei Li; Julia L Hurwitz; Peter Vogel; Charles J Russell
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

5.  Antibody-secreting cells in respiratory tract tissues in the absence of eosinophils as supportive partners.

Authors:  Robert E Sealy; Sherri L Surman; Peter Vogel; Julia L Hurwitz
Journal:  Int Immunol       Date:  2016-07-18       Impact factor: 4.823

6.  B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020.

Authors:  Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-04-29       Impact factor: 2.257

7.  CD4+ T cells support establishment of RSV-specific IgG and IgA antibody secreting cells in the upper and lower murine respiratory tract following RSV infection.

Authors:  Robert E Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Vaccine       Date:  2017-04-11       Impact factor: 3.641

8.  Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.

Authors:  Adrian J Reber; Jin Hyang Kim; Laura A Coleman; Sarah M Spencer; Jessie R Chung; Jufu Chen; Paul Gargiullo; Maria E Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

9.  Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.

Authors:  Rebecca C Brady; Lisa A Jackson; Sharon E Frey; Andi L Shane; Emmanuel B Walter; Geeta K Swamy; Elizabeth P Schlaudecker; Elena Szefer; Mark Wolff; Monica Malone McNeal; David I Bernstein; Mark C Steinhoff
Journal:  Vaccine       Date:  2018-06-28       Impact factor: 3.641

Review 10.  Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.